Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3038% below fair value
$0.53−0.01 (-2.41%)
Close on Nov 13, 2026Market cap $81.19MP/E –Yield –
Coherus Oncology statistics
80 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Mar 8, 2027 (estimated, during market hours)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 11.40
- 2.22
Enterprise valuationIndustry
- EV / Sales
- -0.04
- 2.57
Share statisticsIndustry
- Shares Change (YoY)
- 22.2%
- 10.8%
- Shares Change (QoQ)
- 0.04%
- 0.50%
- Float
- 153M
- 49M
- Shares Held by Insiders
- 1.29%
- 11.7%
- Shares Held by Institutions
- 45.5%
- 56.4%
Short sellingIndustry
- Short Interest
- 13M
- –
- Short Interest Change
- 2.09%
- -0.80%
- Short % of Float
- 8.34%
- 9.01%
- Short % of Shares Outstanding
- 8.23%
- 6.30%
- Days to Cover
- 8.20
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $2.62
- –
- 52-Week Low
- $0.50
- –
- 20-Day Moving Average
- $0.85
- –
- 50-Day Moving Average
- $1.06
- –
- 200-Day Moving Average
- $1.47
- –
- Average True Range (14)
- $0.09
- –
- Price Change (1 Week)
- -31.8%
- -1.15%
- Price Change (1 Month)
- -50.9%
- -4.87%
- Price Change (3 Months)
- -54.3%
- -21.0%
- Price Change (6 Months)
- -66.5%
- -20.6%
- Price Change (YTD)
- -63.0%
- -23.6%
- Price Change (1 Year)
- -61.4%
- -22.4%
- Price Change (3 Years)
- -71.1%
- -29.5%
- Price Change (5 Years)
- -97.2%
- -77.9%
- Price Change (10 Years)
- -98.1%
- -65.4%
- Average Volume (10 Days)
- 3M
- –
- Average Volume (20 Days)
- 2M
- –
- Average Volume (90 Days)
- 1M
- –
- Relative Volume
- 3.07
- 0.70
- Relative Strength Index (14)
- 28.4
- 43.4
- Volatility (1 Year)
- 87.8%
- 80.1%
- Beta (5 Years)
- 1.37
- 1.07
MarginsIndustry
- Pretax Margin
- -289.9%
- -11.6%
- EBITDA Margin
- -274.3%
- -27.7%
Returns on capitalIndustry
- Return on Equity (ROE)
- -240.5%
- -49.9%
- Return on Assets (ROA)
- -39.5%
- -40.6%
- Return on Capital Employed (ROCE)
- -155.0%
- -37.9%
Financial positionIndustry
- Current Ratio
- 1.51
- 3.30
- Quick Ratio
- 1.29
- 2.39
- Interest Coverage
- -15.52
- -6.35
GrowthIndustry
- Revenue Growth (YoY)
- 44.4%
- 6.82%
- Net Income Growth (YoY)
- -187.7%
- -14.4%
- Revenue Growth (3Y CAGR)
- -41.5%
- 2.25%
- Revenue Growth (5Y CAGR)
- -38.4%
- 6.41%
- EPS Growth (5Y CAGR)
- -2.46%
- 3.78%
EfficiencyIndustry
- Asset Turnover
- 0.16
- 0.40
- Inventory Turnover
- 4.71
- 2.73
- Revenue Per Employee
- $364.89K
- $429.29K
- Profits Per Employee
- -$924.73K
- -$689.41K
- Employee Count
- 147
- 74
- WACC
- 11.9%
- 10.2%
Income statement (TTM)Industry
- Pretax Income
- -$155.50M
- -$12.95M
Balance sheetIndustry
- Net Cash (Debt)
- $83.60M
- $17.76M
- Net Cash Per Share
- $0.54
- $0.80
- Equity (Book Value)
- $25.25M
- $53.89M
- Book Value Per Share
- $0.16
- $1.50
- Tangible Book Value
- $7.12M
- $27.13M
- Working Capital
- $38.49M
- $79.99M
Cash flow (TTM)Industry
Dividends and yieldsIndustry
- Earnings Yield
- -167.4%
- -21.8%
Taxes and interestIndustry
- Interest Expense
- $9.54M
- $2.90M
Scores and fair valueIndustry
- Altman Z-Score
- -14.06
- 0.23
- Piotroski F-Score
- 6
- 4
- Beneish M-Score
- 2.81
- -2.63
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | CHRS | S&P 500 | Difference | CHRS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -50.9% | -3.0% | −47.8 pts | ||
| 3 months | -53.9% | -2.8% | −51.1 pts | ||
| Year to date | -63.0% | +11.5% | −74.5 pts | ||
| 1 year | -58.3% | +13.5% | −71.8 pts | ||
| 3 years | -69.4% | +77.7% | −147.1 pts | -32.6% | +21.1% |
| 5 years | -97.2% | +72.6% | −169.8 pts | -51.0% | +11.5% |
| 10 years | -98.1% | +308.2% | −406.3 pts | -32.7% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
13M CHRS shares were sold short on Oct 30, 2026, up 2.1% from the previous report, or 8.34% of the shares available to trade. At recent volumes it would take 8.2 days to buy them back. Over the last 20 sessions, 62.2% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 12,712,857 | +2.1% | 1,551,288 | 8.2 |
| Oct 15, 2026 | 12,452,177 | -46.6% | 1,579,236 | 7.9 |
| Sep 30, 2026 | 23,337,539 | +2.1% | 1,863,260 | 12.5 |
| Sep 15, 2026 | 22,848,985 | -4.5% | 697,553 | 32.8 |
| Aug 31, 2026 | 23,915,667 | -0.3% | 1,420,425 | 16.8 |
| Aug 14, 2026 | 23,997,214 | -2.2% | 1,217,659 | 19.7 |
| Jul 31, 2026 | 24,527,052 | +2.7% | 457,684 | 53.6 |
| Jul 15, 2026 | 23,885,705 | -8.0% | 980,714 | 24.4 |
| Jun 30, 2026 | 25,975,163 | +1.3% | 1,186,988 | 21.9 |
| Jun 15, 2026 | 25,637,521 | -8.0% | 767,402 | 33.4 |
| May 29, 2026 | 27,872,603 | -0.8% | 1,177,971 | 23.7 |
| May 15, 2026 | 28,108,039 | +1.0% | 1,637,849 | 17.2 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?